Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 19/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | GLA | P06280 | 3/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.68 |
| ▸ | TP53 | P04637 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | STAT6 | P42226 | 1/20 | 0.68 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | HNRNPA1 | P09651 | 1/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31142446 | 1.00 | TOP1 (0.78) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL27428824 | 0.93 | TOP1 (0.78) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL6850110 | 0.93 | TOP1 (0.78) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL12633749 | 0.92 | TOP1 (0.77) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL2929566 | 0.92 | TOP1 (0.80) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL26514712 | 0.92 | TOP1 (0.80) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL24513684 | 0.91 | TOP1 (0.75) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL24642753 | 0.91 | TOP1 (0.75) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL6087235 | 0.90 | TOP1 (0.78) | TOP1ALDH1A1GLAKDM4ETP53 | |
| SCHEMBL1385182 | 0.90 | TOP1 (0.83) | TOP1ALDH1A1GLAKDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2023-01-26 | — | — | US | claimed |
| US-11384104-B2 | Delivery systems for controlled drug release | CENTURION BIOPHARMA CORPORATION (US) | 2022-07-12 | — | — | US | claimed |
| EP-3310800-B1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | CENTURION BIOPHARMA CORP (US) | 2021-11-17 | — | — | EP | claimed |
| US-20190002484-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2019-01-03 | — | — | US | claimed |
| EP-3310800-A2 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | CytRx Corporation (US) | 2018-04-25 | — | — | EP | claimed |
| EP-2170900-B1 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM | SIGMA TAU IND FARMACEUTI (IT) | 2012-12-12 | — | — | EP | claimed |
| EP-1828196-B1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA TAU IND FARMACEUTI (IT) | 2012-10-17 | — | — | EP | claimed |
| US-8124769-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-02-28 | — | — | US | claimed |
| US-8101758-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | claimed |
| US-20100311784-A1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPA (IT) | 2010-12-09 | — | — | US | claimed |
| US-20100311783-A1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPA (IT) | 2010-12-09 | — | — | US | claimed |
| US-7799921-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-21 | — | — | US | claimed |
| US-20090239893-A1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-24 | — | — | US | claimed |
| EP-1828196-A2 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2007-09-05 | — | — | EP | claimed |
| WO-2007095389-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH CAMPTOTHECINE N-OXIDE AND ANALOGS | NOVACEA, INC. (US) | 2007-08-23 | — | — | WO | claimed |
| WO-2006067092-A2 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-06-29 | — | — | WO | claimed |
| EP-0056692-B1 | 7-SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-08-14 | — | — | EP | claimed |
| US-4399276-A | 7-Substituted camptothecin derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1983-08-16 | — | — | US | claimed |
| EP-0056692-A1 | 7-Substituted camptothecin derivatives and process for their preparation | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1982-07-28 | — | — | EP | claimed |
| JP-57185285-A | — | — | None | — | — | JP | disclosed |
| US-12497417-B2 | Delivery systems for controlled drug release | LADRX CORPORATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | EDISON ONCOLOGY (US) | 2024-05-16 | — | — | US | disclosed |
| EP-4297746-A2 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED COMPOUNDS AND THERAPIES FOR THE TREATMENT OF DISEASES | Edison Oncology (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2023-01-26 | — | — | US | disclosed |
| CN-115089722-A | Delivery system for controlled drug release | 森托瑞恩生物制药公司 | 2022-09-23 | — | — | CN | disclosed |
| US-11384104-B2 | Delivery systems for controlled drug release | CENTURION BIOPHARMA CORPORATION (US) | 2022-07-12 | — | — | US | disclosed |
| CN-107922457-B | Delivery system for controlled drug release | 森托瑞恩生物制药公司 | 2022-05-13 | — | — | CN | disclosed |
| EP-3954394-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | Centurion BioPharma Corporation (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3310800-B1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | CENTURION BIOPHARMA CORP (US) | 2021-11-17 | — | — | EP | disclosed |
| US-20190002484-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | LADRX CORPORATION | 2019-01-03 | — | — | US | disclosed |
| EP-3310800-A2 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | CytRx Corporation (US) | 2018-04-25 | — | — | EP | disclosed |
| EP-2170900-B1 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM | SIGMA TAU IND FARMACEUTI (IT) | 2012-12-12 | — | — | EP | disclosed |
| EP-1828196-B1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA TAU IND FARMACEUTI (IT) | 2012-10-17 | — | — | EP | disclosed |
| US-8269007-B2 | Crystalline form II of 7-(dimethoxy-methyl) camptothecin, its use as intermediate and products obtained therefrom | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE SPA (IT) | 2012-09-18 | — | — | US | disclosed |
| US-8124769-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-02-28 | — | — | US | disclosed |
| US-8101758-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2012-01-24 | — | — | US | disclosed |
| US-20100311784-A1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPA (IT) | 2010-12-09 | — | — | US | disclosed |
| US-20100311783-A1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITIE SPA (IT) | 2010-12-09 | — | — | US | disclosed |
| US-20100249414-A1 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-30 | — | — | US | disclosed |
| US-7799921-B2 | Stereoselective process and crystalline forms of a camptothecin | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-09-21 | — | — | US | disclosed |
| US-7705012-B2 | Camptothecins conjugated in position 7 to cyclic peptides as cytostatic agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2010-04-27 | — | — | US | disclosed |
| EP-2170900-A1 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2010-04-07 | — | — | EP | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | BOOJAMRA CONSTANTINE G | 2010-01-28 | — | — | US | disclosed |
| US-7629003-B2 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-12-08 | — | — | US | disclosed |
| US-7612081-B2 | 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) | 2009-11-03 | — | — | US | disclosed |
| US-20090239893-A1 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-24 | — | — | US | disclosed |
| US-7585519-B2 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-08 | — | — | US | disclosed |
| WO-2009016068-A1 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-02-05 | — | — | WO | disclosed |
| EP-1753776-B1 | CAMPTOTHECINS CONJUGATED IN POSITION 7 TO CYCLIC PEPTIDES AS CYTOSTATIC AGENTS | SIGMA TAU IND FARMACEUTI (IT) | 2009-01-14 | — | — | EP | disclosed |
| EP-1603919-B1 | 7-IMINO DERIVATIVES OF CAMPTOTHECIN HAVING ANTITUMOR ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2008-12-17 | — | — | EP | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7452901-B2 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2008-11-18 | — | — | US | disclosed |
| US-7351714-B2 | 7-imino derivatives of camptothecin having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-04-01 | — | — | US | disclosed |
| CN-100372855-C | 7-imino derivatives of camptothecin having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2008-03-05 | — | — | CN | disclosed |
| US-20080033003-A1 | Camptothecins Conjugated in Position 7 to Cyclic Peptides as Cytostatic Agents | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2008-02-07 | — | — | US | disclosed |
| EP-1828196-A2 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007095389-A2 | TREATMENT OF HYPERPROLIFERATIVE DISEASES WITH CAMPTOTHECINE N-OXIDE AND ANALOGS | NOVACEA, INC. (US) | 2007-08-23 | — | — | WO | disclosed |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-08-16 | — | — | US | disclosed |
| US-20070043067-A1 | 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-02-22 | — | — | US | disclosed |
| EP-1753776-A1 | CAMPTOTHECINS CONJUGATED IN POSITION 7 TO CYCLIC PEPTIDES AS CYTOSTATIC AGENTS | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. (IT) | 2007-02-21 | — | — | EP | disclosed |
| US-7105492-B2 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-09-12 | — | — | US | disclosed |
| US-20060167033-A1 | 7-Imino derivatives of camptothecin having antitumor activity | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) | 2006-07-27 | — | — | US | disclosed |
| WO-2006067092-A2 | STEREOSELECTIVE PROCESS AND CRYSTALLINE FORMS OF A CAMPTOTHECIN | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2006-06-29 | — | — | WO | disclosed |
| CN-1780631-A | anticancer phosphonate analogs | GILEAD SCIENCES INC (US) | 2006-05-31 | — | — | CN | disclosed |
| EP-1656380-A2 | 7-POLYAMINOALKYL(OXY)IMINOMETHYLCAMPTOTHECINS BEARING PROTECTIVE GROUPS | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2006-05-17 | — | — | EP | disclosed |
| CN-1761668-A | 7-imino derivatives of camptothecin having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2006-04-19 | — | — | CN | disclosed |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | GILEAD SCIENCES, INC. | 2006-04-13 | — | — | US | disclosed |
| EP-1426044-B1 | Use of esters of L-carnitine or alkanoyl L-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA TAU IND FARMACEUTI (IT) | 2006-02-08 | — | — | EP | disclosed |
| EP-1617848-A2 | ANTI-CANCER PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2006-01-25 | — | — | EP | disclosed |
| EP-1603919-A1 | 7-IMINO DERIVATIVES OF CAMPTOTHECIN HAVING ANTITUMOR ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005111063-A1 | CAMPTOTHECINS CONJUGATED IN POSITION 7 TO CYCLIC PEPTIDES AS CYTOSTATIC AGENTS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-11-24 | — | — | WO | disclosed |
| US-20050079209-A1 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. | 2005-04-14 | — | — | US | disclosed |
| EP-1499617-A1 | CAMPTOTHECIN-TAXOID CONJUGATES AS ANTIMITOTIC AND ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-01-26 | — | — | EP | disclosed |
| WO-2005005431-A2 | 7-POLYAMINOALKYL(OXY)IMINOMETHYLCAMPTOTHECINS BEARING PROTECTIVE GROUPS | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2005-01-20 | — | — | WO | disclosed |
| EP-1183228-B1 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES USEFUL AS CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS. | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-12 | — | — | EP | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004083214-A1 | 7-IMINO DERIVATIVES OF CAMPTOTHECIN HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-30 | — | — | WO | disclosed |
| US-6797281-B1 | Esters of I-carnitine or alkanoyl I-carnitines | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-28 | — | — | US | disclosed |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| EP-1426044-A1 | Use of esters of L-carnitine or alkanoyl L-carnitines as cationic lipids for the intracellular delivery of pharmacologically active compounds | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2004-06-09 | — | — | EP | disclosed |
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-01-29 | — | — | US | disclosed |
| WO-2003093274-A1 | CAMPTOTHECIN-TAXOID CONJUGATES AS ANTIMITOTIC AND ANTITUMOR AGENTS | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2003-11-13 | — | — | WO | disclosed |
| US-6593334-B1 | Compounds according to formula I: C'-L-T (I), wherein C' is a camptothecin group; L is a linking moiety; T is a taxoid group, pharmaceutically acceptable salt thereof. The compounds are useful in, among other things, treating cancer | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2003-07-15 | — | — | US | disclosed |
| US-6589939-B2 | Also useful in treating viral infections; antiprotozoa (plasmodium) activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-07-08 | — | — | US | disclosed |
| CN-1107677-C | Camptothecin derivatives and use thereof as antimutor agents | IST NAZ STUD CURA DEI TUMORI (IT) | 2003-05-07 | — | — | CN | disclosed |
| EP-0885230-B1 | CAMPTOTHECIN DERIVATIVES AND THE USE THEREOF AS ANTITUMOR AGENTS | IST NAZ STUD CURA DEI TUMORI (IT) | 2002-07-24 | — | — | EP | disclosed |
| EP-1044977-B1 | Camptothecin derivatives having antitumor activity | SIGMA TAU IND FARMACEUTI (IT) | 2002-05-02 | — | — | EP | disclosed |
| EP-1183228-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-03-06 | — | — | EP | disclosed |
| US-6306868-B1 | ISOMERS OF FOR ANTITUMOR AGENTS | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) | 2001-10-23 | — | — | US | disclosed |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A.. | 2001-07-19 | — | — | US | disclosed |
| US-6242457-B1 | OXIME DERIVATIVES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2001-06-05 | — | — | US | disclosed |
| WO-2000061543-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-19 | — | — | WO | disclosed |
| EP-1044977-A1 | Camptothecin derivatives having antitumor activity | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2000-10-18 | — | — | EP | disclosed |
| US-6130227-A | 7-Substituted camptothecin derivatives and methods for inhibiting the growth of tumor cells therewith | ISTITUTO NAZIONAL PER LO STUDIO E LA CURA DEI TUMORI (IT) | 2000-10-10 | — | — | US | disclosed |
| WO-2000053607-A1 | CAMPTOTHECIN DERIVATIVES HAVING ANTITUMOR ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-09-14 | — | — | WO | disclosed |
| US-6100273-A | TOPOISOMERASE INHIBITOR ANTITUMOR AGENT | GLAXO WELLCOME INC. (US) | 2000-08-08 | — | — | US | disclosed |
| CN-1211987-A | Camptothecin derivatives and use thereof as antimutor agents | IST NAZ STUD CURA DEI TUMORI (IT) | 1999-03-24 | — | — | CN | disclosed |
| EP-0885230-A1 | CAMPTOTHECIN DERIVATIVES AND THE USE THEREOF AS ANTITUMOR AGENTS | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) | 1998-12-23 | — | — | EP | disclosed |
| WO-1997031003-A1 | CAMPTOTHECIN DERIVATIVES AND THE USE THEREOF AS ANTITUMOR AGENTS | ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI (IT) | 1997-08-28 | — | — | WO | disclosed |
| US-5559235-A | ANTITUMOR | GLAXO WELLCOME INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0540099-B1 | Water soluble camptothecin derivatives | GLAXO WELLCOME INC (US) | 1996-04-17 | — | — | EP | disclosed |
| EP-0696285-A1 | WATER SOLUBLE DERIVATIVES OF CAMPTOTHECIN AND THEIR USE AS ANTITUMOR AGENTS | GLAXO WELLCOME INC. (US) | 1996-02-14 | — | — | EP | disclosed |
| EP-0673380-A1 | WATER SOLUBLE CAMPTOTHECIN DERIVATIVES | GLAXO WELLCOME INC. (US) | 1995-09-27 | — | — | EP | disclosed |
| WO-1994025466-A1 | WATER SOLUBLE DERIVATIVES OF CAMPTOTHECIN AND THEIR USE AS ANTITUMOR AGENTS | GLAXO WELLCOME INC. (US) | 1994-11-10 | — | — | WO | disclosed |
| CN-1091742-A | Water soluble camptothecin derivatives | GLAXO INC (US) | 1994-09-07 | — | — | CN | disclosed |
| US-5342947-A | Treating alkylenedioxy-7-trihaloacetamidomethylenecamptothecin with hydrochloric or sulfuric acid to yield amine salt, treating with alkali metal hydroxide or carbonate to obtain free base | GLAXO INC. (US) | 1994-08-30 | — | — | US | disclosed |
| WO-1994011377-A2 | WATER SOLUBLE CAMPTOTHECIN DERIVATIVES | GLAXO INC. (US) | 1994-05-26 | — | — | WO | disclosed |
| EP-0540099-A1 | Water soluble camptothecin derivatives | GLAXO WELLCOME INC. (US) | 1993-05-05 | — | — | EP | disclosed |
| EP-0137145-B1 | NEW CAMPTOTHECIN DERIVATIVES AND PROCESS FOR PREPARING SAME | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1988-04-27 | — | — | EP | disclosed |
| US-4604463-A | ANTITUMOR AGENTS | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1986-08-05 | — | — | US | disclosed |
| EP-0056692-B1 | 7-SUBSTITUTED CAMPTOTHECIN DERIVATIVES AND PROCESS FOR THEIR PREPARATION | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-08-14 | — | — | EP | disclosed |
| US-4513138-A | Camptothecin-1-oxide derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-04-23 | — | — | US | disclosed |
| EP-0137145-A1 | New camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1985-04-17 | — | — | EP | disclosed |
| US-4473692-A | Camptothecin derivatives and process for preparing same | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1984-09-25 | — | — | US | disclosed |
| US-4399276-A | 7-Substituted camptothecin derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1983-08-16 | — | — | US | disclosed |
| US-4399276-A | 7-Substituted camptothecin derivatives | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1983-08-16 | — | — | US | disclosed |
| JP-S57185285-A | NOVEL CAMPTOTHECIN DERIVATIVE | YAKULT HONSHA CO LTD | 1982-11-15 | — | — | JP | disclosed |
| EP-0056692-A1 | 7-Substituted camptothecin derivatives and process for their preparation | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1982-07-28 | — | — | EP | disclosed |
| EP-0056692-A1 | 7-Substituted camptothecin derivatives and process for their preparation | KABUSHIKI KAISHA YAKULT HONSHA (JP) | 1982-07-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033003-A1 | Camptothecins Conjugated in Position 7 to Cyclic Peptides as Cytostatic Agents | ITGA5, ITGB5, ITGB7 | TOP1 67/4885ALDH1A1 3178/4885GLA 1864/4885 |
| US-20050079209-A1 | Esters of L-carnitine of alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SLC25A20, CRAT, CPT1B | TOP1 2670/4885ALDH1A1 628/4885GLA 1797/4885 |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CPT1B, SLC25A20, CRAT | TOP1 1887/4885ALDH1A1 461/4885GLA 1964/4885 |
| US-20190002484-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885ALDH1A1 830/4885GLA 3131/4885 |
| US-20060167033-A1 | 7-Imino derivatives of camptothecin having antitumor activity | TYMP, TOP1, TOP2A | TOP1 2/4885ALDH1A1 2013/4885GLA 2726/4885 |
| US-20240156808-A1 | Compositions and methods to improve the therapeutic benefit of suboptimally chemical compounds and biological therapies including substituted camptothecins such as irinotecan and topotecan for the treatment of benign and neoplastic hyperproliferative disease conditions, infections, inflammatory and immunological diseases | TOP2A, TOP2B, TOP1 | TOP1 3/4885ALDH1A1 3441/4885GLA 1569/4885 |
| US-20100249414-A1 | CRYSTALLINE FORM II OF 7-(DIMETHOXY-METHYL) CAMPTOTHECIN, ITS USE AS INTERMEDIATE AND PRODUCTS OBTAINED THEREFROM | TOP2B, TOP2A, TOP1 | TOP1 3/4885ALDH1A1 2545/4885GLA 3272/4885 |
| US-11384104-B2 | Delivery systems for controlled drug release | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885ALDH1A1 830/4885GLA 3131/4885 |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CRAT, SLC25A20, CPT1B | TOP1 2678/4885ALDH1A1 637/4885GLA 1731/4885 |
| US-20060079478-A1 | Anti-cancer phosphonate analogs | PIK3CA, PHOSPHO1, PTEN | TOP1 126/4885ALDH1A1 3678/4885GLA 810/4885 |
| US-20230023537-A1 | DELIVERY SYSTEMS FOR CONTROLLED DRUG RELEASE | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885ALDH1A1 830/4885GLA 3131/4885 |
| US-20010008939-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TYMP | TOP1 1/4885ALDH1A1 2202/4885GLA 1623/4885 |
| US-20040018988-A1 | Camptothecin derivatives having antitumor activity | TOP1, TOP2A, TOP2B | TOP1 1/4885ALDH1A1 1248/4885GLA 1972/4885 |
| US-20100022467-A1 | ANTI-CANCER PHOSPHONATE ANALOGS | PIK3CA, PHOSPHO1, PTEN | TOP1 126/4885ALDH1A1 3678/4885GLA 810/4885 |
| US-20070043067-A1 | 7-Polyaminoalkyl(oxy)iminomethylcamptothecins bearing protective groups | TOP2B, TOP2A, TOP1 | TOP1 3/4885ALDH1A1 2277/4885GLA 2663/4885 |
| US-12497417-B2 | Delivery systems for controlled drug release | ABCB11, SLC10A1, SLC5A1 | TOP1 1182/4885ALDH1A1 830/4885GLA 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.